Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Editor
Washington DC, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}
+14 year(s) experience
Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals.He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association.
Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other. Other passions: crowd sourcing, data mining, classic movies and working on his basketball game.
Pink Sheet
By Bowman Cox 22 Aug 2018
When firms are developing highly anticipated gene therapies, it’s important to establish GMP-controlled manufacturing processes earlier in development, as Sarepta discovered when US FDA placed a clinical hold on a promising Duchenne muscular dystrophy gene therapy.
Topic FDA
Scrip
By Bowman Cox 23 Feb 2018
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
Topic FDA Business strategies
Pink Sheet
By Bowman Cox 25 Oct 2017
The race is on in Puerto Rico to avert critical drug shortages that could hit the US in a few months if service from the island's electrical grid hasn't been restored.
Topic BioPharmaceutical
Pink Sheet
By Bowman Cox 02 Feb 2017
Followers of rogue FDA twitter site AltFDA answered a call to back up inspection citations data the Obama administration made public in case the Trump administration erases it from the FDA website.
Topic us-election
Pink Sheet
By Bowman Cox 17 Jan 2017
Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.
Pink Sheet
10 Dec 2019
Pink Sheet
06 Dec 2019
Pink Sheet
06 Dec 2019
Pink Sheet
04 Dec 2019
Pink Sheet
28 Nov 2019
Pink Sheet
27 Nov 2019
Pink Sheet
20 Nov 2019
Pink Sheet
14 Nov 2019
Pink Sheet
12 Nov 2019
Pink Sheet
03 Nov 2019
Pink Sheet
31 Oct 2019
Pink Sheet
17 Oct 2019
Pink Sheet
16 Oct 2019
Pink Sheet
11 Oct 2019
Pink Sheet
04 Oct 2019
